Sarepta Therapeutics
SRPT · NASDAQ
Bulios Fair Price
$28.83
43.3% upside
Current Price
$20.12
According to Bulios Fair Price, SRPT is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Sarepta Therapeutics, Inc. (SRPT) is an American biopharmaceutical company focused on research, development, and commercialization of drugs for the treatment of rare genetic diseases. The company specializes in treating muscular dystrophies caused by genetic mutations. Sarepta Therapeutics develops innovative therapies based on gene therapy and RNA technologies, which have the potential to provide new treatment options for patients with rare genetic diseases. With its successful research programs and collaboration with renowned experts in the field, the company has become a significant player in the field of muscular dystrophy treatment. Shares of Sarepta Therapeutics, Inc. (SRPT) can represent an interesting investment opportunity for those seeking exposure to the biotechnology industry with a focus on treating rare genetic diseases and innovative therapeutic approaches.
Sector
Healthcare
Industry
Biotechnology
CEO
Michael E. Severino
Employees
835
Headquarters
Cambridge
Upcoming events
Earnings
Upcoming earnings report